Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Supplemental Table 1. Baseline Patient Demographics and Disease Characteristics

	Cohort A1 (3 mg) N = 3	Cohort A2 (10 mg) N = 3	Cohort A3 (30 mg) N = 3	Cohort A4 (70 mg) N = 3
Sex, n				
Female	2	2	1	1
Male	1	1	2	2
Median age (range), years	52 (52-56)	52 (49-70)	56 (25-64)	54 (53-60)
Race, n				
Caucasian	1	2	3	2
Asian	2	1	0	1
Tumor type, n				
Breast cancer	1[a]	2 (1[a] and 1[b])	-	1[c]
Non-small cell lung cancer	1[b]	1[b]	-	-
Rectal cancer	1[b]	-	-	1[d]
Peritoneal sarcoma	-	-	1[b]	-
Desmoplastic small round cell tumor	-	-	1[d]	-
Ovarian cancer	-	-	1[e]	-
Ductal adenocarcinoma of pancreas	-	-	-	1[d]
Prior anticancer therapies, n				
Median number (IQR)	5 (1-5)	6 (1-9)	4 (3-10)	5 (4-10)
1 prior line	1	1	0	0
≥3 prior lines	2	2	3	3
Surgical procedure	2	2	3	3
Radiotherapy	0	2	3	3
Systemic therapy	3	3	3	3

N and n are numbers of patients.
Histopathological diagnosis grade: [a] poorly differentiated high grade, [b] unable to determine, [c] undifferentiated high grade, [d] well differentiated low grade, [e] not reported.